N-acetylcysteine (NAC) in the treatment of Obsessive-Compulsive Disorder (OCD)
Both males and females
18 years to 70 years
A 24-week, double blind placebo study investigating the effects of the amino acid ‘N-acetylcysteine’ (NAC) in Obsessive-Compulsive Disorder (OCD). This NHMRC funded study is currently enrolling participants at 3 trial sites – The University of Melbourne, University of Queensland and Western Sydney University.
Eligible participants will be randomised to receive NAC (2,000mg – 4,000mg) or placebo adjunctive to stable pharmacotherapy for a period of 6-months.
Phone Number: 03) 9487 4659
Location: 2 Salisbury St, Richmond, Victoria, Australia
Butterfield St, Herston, Queensland, Australia
Campbelltown, New South Wales, Australia
Approved By: TMC Research Ethics Committee
Clinical Trial Registry Link: